Rexahn Looks For Breakthrough Year With Three Clinical Candidates
Executive Summary
Rexahn Pharmaceuticals hopes this will be its big year. With three candidates in various stages of Phase II development and cash projected to last through the first quarter of 2011, Rexahn feels it should be able to land at least one major deal to either co-develop or out-license one its lead programs
You may also be interested in...
Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings
The Rockville, Md.-based biotech hopes to bring more value to shareholders through a slew of polymer-conjugated cancer drugs that it will add to its pipeline while it continues moving its three lead cancer compounds forward.
FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
FDA Commissioner Margaret Hamburg said the agency's infrastructure is not where it needs to be in order to pursue nanotechnology initiatives
FDA Not Ready For The Nanotechnology Surge; Infrastructure - Not Technical Capability - Is The Challenge, Hamburg Says
FDA Commissioner Margaret Hamburg said the agency's infrastructure is not where it needs to be in order to pursue nanotechnology initiatives